| Title |
Triptans for the Management of Migraine
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/11537990-000000000-00000 |
| Pubmed ID | |
| Authors |
Mollie M. Johnston, Alan M. Rapoport |
| Abstract |
Migraine is a chronic, recurrent, disabling condition that affects millions of people in the US and worldwide. Proper acute care treatment for migraineurs is essential for a full return of function and productivity. Triptans are serotonin (5-HT)(1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. All triptans are superior to placebo in clinical trials, and some, such as rizatriptan 10 mg, eletriptan 40 mg, almotriptan 12.5 mg, and zolmitriptan 2.5 and 5 mg are very similar to each other and to the prototype triptan, sumatriptan 100 mg. These five are known as the fast-acting triptans. Increased dosing can offer increased efficacy but may confer a higher risk of adverse events, which are usually mild to moderate and transient in nature. This paper critically reviews efficacy, safety and tolerability for the different formulations of sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan and frovatriptan. |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| Netherlands | 1 | <1% |
| Unknown | 119 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 15% |
| Student > Bachelor | 15 | 12% |
| Researcher | 13 | 11% |
| Student > Ph. D. Student | 13 | 11% |
| Student > Postgraduate | 7 | 6% |
| Other | 15 | 12% |
| Unknown | 41 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 25% |
| Neuroscience | 11 | 9% |
| Agricultural and Biological Sciences | 10 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 7% |
| Nursing and Health Professions | 5 | 4% |
| Other | 16 | 13% |
| Unknown | 40 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 February 2019.
All research outputs
#3,070,629
of 25,371,288 outputs
Outputs from Drugs
#401
of 3,464 outputs
Outputs of similar age
#21,275
of 188,975 outputs
Outputs of similar age from Drugs
#110
of 1,509 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,975 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1,509 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.